First National Bank of Mount Dora Trust Investment Services Cuts Stake in Johnson & Johnson (NYSE:JNJ)

First National Bank of Mount Dora Trust Investment Services cut its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,057 shares of the company’s stock after selling 641 shares during the quarter. First National Bank of Mount Dora Trust Investment Services’ holdings in Johnson & Johnson were worth $5,033,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. PDS Planning Inc increased its position in shares of Johnson & Johnson by 5.2% during the third quarter. PDS Planning Inc now owns 14,842 shares of the company’s stock worth $2,405,000 after acquiring an additional 729 shares during the last quarter. QRG Capital Management Inc. increased its holdings in Johnson & Johnson by 5.9% in the third quarter. QRG Capital Management Inc. now owns 494,125 shares of the company’s stock valued at $80,078,000 after buying an additional 27,484 shares during the last quarter. Asset Management One Co. Ltd. increased its holdings in Johnson & Johnson by 0.8% in the third quarter. Asset Management One Co. Ltd. now owns 1,154,982 shares of the company’s stock valued at $187,176,000 after buying an additional 9,585 shares during the last quarter. FIDELIS iM LLC bought a new stake in Johnson & Johnson in the third quarter valued at about $206,000. Finally, National Pension Service increased its holdings in Johnson & Johnson by 14.3% in the third quarter. National Pension Service now owns 4,567,654 shares of the company’s stock valued at $740,234,000 after buying an additional 570,265 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $158.24 on Tuesday. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market capitalization of $380.98 billion, a PE ratio of 22.90, a PEG ratio of 2.84 and a beta of 0.53. The business’s 50 day moving average is $163.18 and its 200-day moving average is $155.68. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.66 EPS. Sell-side analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.13%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JNJ shares. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada lifted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, Citigroup lifted their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.